SCHEMBL30487565

SCHEMBL30487565

Fc1ccc(CNc2ncnc3nc[nH]c23)c(F)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.66
AURKA O14965 2/20 0.66
AURKB Q96GD4 2/20 0.66
CDK5 Q00535 2/20 0.66
DAPK3 O43293 1/20 0.66
JAK2 O60674 1/20 0.66
PRKD3 O94806 1/20 0.66
MAP4K4 O95819 1/20 0.66
PAK4 O96013 1/20 0.66
ABL1 P00519 1/20 0.66
LCK P06239 1/20 0.66
CSF1R P07333 1/20 0.66
RET P07949 1/20 0.66
PDGFRB P09619 1/20 0.66
FGFR1 P11362 1/20 0.66
PRKACA P17612 1/20 0.66
FLT1 P17948 1/20 0.66
LTK P29376 1/20 0.66
GRK5 P34947 1/20 0.66
MAP2K2 P36507 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4927021 1.00 KDR (0.66) KDRAURKAAURKBCDK5DAPK3
SCHEMBL4914102 0.90 KDR (0.66) KDRAURKAAURKBCDK5DAPK3
SCHEMBL4925463 0.89 KDR (0.65) KDRAURKAAURKBCDK5DAPK3
SCHEMBL4925677 0.88 KDR (0.57) KDRAURKAAURKBCDK5DAPK3
SCHEMBL4924728 0.88 LMNA (0.70) KDRAURKAAURKBCDK5DAPK3
SCHEMBL4917816 0.85 KDR (0.61) KDRAURKAAURKBCDK5DAPK3
SCHEMBL4926005 0.85 KDR (0.55) KDRAURKAAURKBCDK5DAPK3
SCHEMBL4926156 0.85 KDR (0.60) KDRAURKAAURKBCDK5DAPK3
SCHEMBL4926206 0.85 KDR (0.63) KDRAURKAAURKBCDK5DAPK3
SCHEMBL4921517 0.85 KDR (0.63) KDRAURKAAURKBCDK5DAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570657-B2 Mesylate salts of heterocyclic cytokinins, compositions containing these derivatives and use thereof UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2026-03-10 US disclosed
US-20230192697-A1 MESYLATE SALTS OF HETEROCYCLIC CYTOKININS, COMPOSITIONS CONTAINING THESE DERIVATIVES AND USE THEREOF UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2023-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192697-A1 MESYLATE SALTS OF HETEROCYCLIC CYTOKININS, COMPOSITIONS CONTAINING THESE DERIVATIVES AND USE THEREOF MAT1A, MAT2A, MAT2B KDR 2669/4885AURKA 1568/4885AURKB 1057/4885
US-12570657-B2 Mesylate salts of heterocyclic cytokinins, compositions containing these derivatives and use thereof TYMP, TK1, DCK KDR 2752/4885AURKA 854/4885AURKB 600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.